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ABST RACT
Aim. We aimed to compare the local therapeutic efficiency of microwave ablation
(MWA), surgical resection, and combined treatment, assess the outcomes, and
identify predictive factors for local treatment response in colorectal liver
metastases (CLMs). Methods. From March 2013 to September 2019, a total of 54
patients with 302 CLMs were enrolled in this retrospective study. Eleven patients
(20.4%) were treated with MWA, 9 patients (16.7%) with surgery, and 34 patients
(63%) with the combined method. Univariate and multivariate analyses were
performed to investigate overall survival (OS) and hepatic progression-free
survival (HPFS) using the Cox proportional hazard regression model. The logistic
regression analysis was used to identify the predictive factors for the local
treatment response. Results. Total treatment response was achieved in 46.3%
(n=25) of the patients. Local tumor progression was seen in 7.4% (n=4) of the
patients, and the rate of intrahepatic distal recurrence was 46.3% (n=25). There
were no significant differences in HPFS and OS between the three groups (p=0.56
and 0.90, respectively). Younger age (<60), smaller (≤ 2 cm) or fewer (≤3) liver
metastases, and wild-type RAS were predictive for higher rates of local treatment
response (OR 0.22, 95% CI 0.15-0.93, p=0.04; OR 1.12, 95% CI 0.54-2.12,
p=0.029; OR 1.37, 95% CI 0.97-2.37, p=0.035; OR 0.23, 95% CI 0.10-0.85,
p=0.028, respectively). Conclusions. The results of this study reveal that the use
of MWA, alone or combined with resection, may achieve high local treatment
response and similar survival rates compared to patients undergoing resection,
suggesting that MWA could potentially be preferred over surgical procedures.

Introduction
Colorectal cancer (CRC) is the third leading cause of
death worldwide [1]. At the time of the diagnosis, almost
25% of the patients present with synchronous liver
metastases [2]. Only 10% of the CRC patients with liver
metastases are candidates for surgical resection due to latestage cancer, anatomic restrictions, comorbidities, or
limited liver reserve [3]. Several guidelines consider
surgery as the first-line treatment for colorectal liver
metastases (CLMs) and recommend the use of ablation
techniques as a suitable option for unresectable tumors. In
contrary to the surgical resection, ablation techniques
enable the preservation of the liver volume and, therefore,
allow re-intervention in the setting of any local tumor
progression (LTP) or intrahepatic distant recurrence (IDR)
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[4-6]. Because of the aging patient population with more
comorbidities and possible liver damage due to
chemotherapy, less invasive ablative treatments including
radiofrequency ablation (RFA) and microwave ablation
(MWA) are gaining more importance in the curative-intent
treatment.
Various studies in the literature investigate the
efficiency of different thermal ablation techniques in
heterogeneous patient populations, mostly with
hepatocellular carcinoma or miscellaneous metastases [711]. This study focusing solely on MWA of CLMs
regarding the thermal ablation method differs from prior
studies. Our aim is to compare the overall survival (OS),
and the hepatic progression-free survival (HPFS) of MWA,
surgical resection, and combined method, and also to
determine predictive factors for local treatment response.
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Materials and Methods
The choice of treatment was made by a
multidisciplinary tumor board in a case-based manner. The
local non-interventional clinical research ethics board
approved the study (decision number 749, date of approval
12.19.2018). The informed consent was obtained from all
individual participants included in the study.
Inclusion criteria and data collection
From March 2013 to September 2019, the data from
patients with CLMs were retrospectively analyzed. After
excluding nine patients lost to follow-up, fifty-four patients
with 302 CLMs were included in the study.
Patients with advanced-stage cancer, poor liver reserve,
anatomic restrictions, severe comorbidities, or refusing the
surgical resection were deemed MWA candidates.
Moreover, patients having less than 25 CLMs with a
maximum diameter smaller than 5 cm were considered
suitable for intraoperative MWA. In the combined
treatment, MWA was preferred in small lesions located
deep in the hepatic parenchyma or near vasculo-biliary
structures, which were difficult to reach in surgery.
The patients’ data including age, gender, type of
surgery, histopathology, stage, ECOG (Eastern
Cooperative Oncology Group) performance status, Rat
sarcoma viral oncogene homologous (RAS) mutation
status, the number and diameter of liver metastases, the
systemic chemotherapy and/or radiation therapy, the
responses to treatment, and the survival rate were
retrospectively collected from the patients’ charts.
CRCs were initially diagnosed by pathological
evaluation of endoscopic biopsy or surgical resection
specimens, whereas the diagnosis of liver metastases was
made according to the characteristic imaging features. RAS
mutation status was investigated only in primary CRC
tumor specimens.
Procedures
Percutaneous MWA was performed under conscious
sedation, whereas general anesthesia was preferred in
surgical treatments. The surgical resection comprised
either partial hepatectomy or metastasectomy. Microwave
ablation was performed with Acculis/Solero Microwave
Tissue Ablation System (Angiodynamics, New York,
USA), including generator and 15.5 G internally cooled
antenna. An energy output between 60-140 W for a period
of 2-6 min was preferred to ablate the lesion with at least 5
mm of the surrounding liver parenchyma. US (LOGIQ S8,
Waukesha, Wisconsin, USA) enabled real-time monitoring
of the antenna position and the size of the ablation zone.
IOUS was performed routinely in surgery and combined
treatment to identify metastases not detected
preoperatively and to confirm the relationship with the
adjacent vasculo-biliary structures. At the end of the
session, the applicator track was ablated to prevent any
tumor seeding. All IOUS and MWA were performed by a
126

single interventional radiologist with 15 years of
experience (CE).
Follow-up imaging
All patients were followed up with 256-slice CT
(Brilliance iCT, Philips, Eindhoven, The Netherlands) or
MRI (Ingenia 1.5T, Philips, Best, The Netherlands and
Achieva 3.0T-x, Philips, Best, The Netherlands) one month
after the treatment, every 3 months for the first year and
every 6 months thereafter. The median follow-up time of
the study was 27.7 months (ranging from 8.2 to 126
months). Contrast enhanced CT or MRI were utilized to
assess the treatment efficiency. According to the
Cardiovascular and Interventional Radiological Society of
Europe (CIRSE) standards, a non-enhancing area larger
than the index tumor with or without peripheral rim-like
enhancement following ablation was regarded as complete
ablation, whereas scattered, nodular or peripheral rim
enhancement was categorized as incomplete ablation [12].
LTP was defined as the presence of a new tumor at the
border of the ablation on the follow-up imaging. IDR
represented a new tumor elsewhere in the liver. Local
tumor control and local tumor response were used
interchangeably referring to the absence of any LTP or IDR
following a complete ablation.
According to the Society of Interventional Radiology
guidelines, complications resolving spontaneously without
treatment were classified as minor, while those requiring
treatment or hospitalization were defined as major
complications [13]. The OS was calculated from the day of
the primary tumor diagnosis until death or the day of the
last follow-up. HPFS was defined as the time between the
local treatment procedure and the detection of any LTP/
IDR or the last follow-up.
Statistical analysis
All statistical analyses were conducted using SPSS 22.0
(SPSS Inc., Chicago, IL, USA). The relationship between
local treatment modalities and clinico-pathological factors
was analyzed with the chi-square and the Fischer’s exact
test. Univariate and multivariate analyses were performed
to assess the overall and hepatic progression-free survival
using the Cox proportional hazard regression model.
Logistic regression analysis was used to identify the
predictive factors for the local treatment response. Both OS
and HPFS were analyzed using the Kaplan-Meier
estimates, and comparisons were performed using the log
rank test. All statistical tests were two-sided, and p values
<0.05 were considered statistically significant.

Results
In the study population, 27.8% were women (n=15) and
72.2% were (n=39) men. The patients’ ages ranged from
30 to 83 and the median age was 62. The number of CLMs
varied from 1 to 27 and the median lesion number was 4.
The median size of metastases was 20 mm (range 2-80
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mm). The original tumor was colon cancer in 32 (59.3%)
of the patients and rectal cancer in 22 (40.7%) of them. All
patients were treated with systemic chemotherapy plus
targeted agents. A total of 17 (31.5%) patients received
neoadjuvant chemotherapy regimen, whereas 2 (3.7%)
patients received neoadjuvant radiotherapy for the primary
tumor and 10 (18.5%) patients underwent chemoradiotherapy.
In 20.4% of the patients (n=11) MWA was performed,
in 16.7% (n=9) of the patients, surgical resection was
performed, and in 63% (n=34) of them, combined
treatment was conducted. In 6 patients, partial hepatectomy
was performed, while in 39 patients metastasectomy was

preferred. A total of 3 (7%) of the MWA sessions were
performed under CT/US-guidance and 42 (93%) sessions
were conducted with IOUS. IOUS was performed either
during metastasectomy or colectomy.
The relationship between local treatment modalities
and clinicopathological factors are summarized in Table 1.
Our study groups showed similar baseline characteristics,
with the exception of the primary tumor location, the
number of metastases and the extrahepatic progression
following the treatment. Major complications including
biloma, hepatic abscess and pleural effusion occurred in
20% (n=25) of the patients, whereas minor complications
were encountered in 17% (n=9) of the patients.

Table 1. The relationship between local treatment modalities and clinicopathological factors
Factor

MWA
n (%)

MWA+ surgery
n (%)

Surgery
n (%)

P

Gender
0.30
Female
1 (9.1)
11 (32.4)
3 (33.3)
Male
10 (90.9)
23 (67.6)
6 (66.7)
Age (year)
0.23
<60
6 (54.5)
18 (52.9)
2 (22.2)
>60
5 (45.5)
16 (47.1)
7 (77.8)
ECOG PS
0.18
0
2 (18.2)
6 (17.6)
1 (11.1)
1
6 (54.5)
27 (79.4)
7 (77.8)
2
3 (27.3)
1 (2.9)
1 (11.1)
RAS mutation
0.17
Wild type
3 (27.3)
19 (57.5)
4 (40.0)
Mutant
8 (72.7)
14 (42.5)
6 (60.0)
Primary tumor location
0.015
Colon
3 (27.3)
25 (78.5)
4 (44.4)
Rectum
8 (72.7)
9 (26.5)
5 (55.6)
Time of liver metastasis occurrence
0.12
Synchronous
8 (72.7)
30 (90.9)
10 (100)
Metachronous
3 (27.3)
3 (9.1)
0
Metastasis location
0.22
Right lobe
7 (53.8)
15 (53.5)
6 (46.2)
Left lobe
6 (46.2)
13 (46.5)
7 (53.8)
Diameter of the largest metastasis (mm)
0.18
0-10 mm
6 (54.5)
5 (14.7)
0
11-20 mm
2 (18.2)
13 (38.2)
5 (55.6)
21-30 mm
2 (18.2)
8 (23.5)
2 (22.2)
31-40 mm
1 (9.1)
2 (5.9)
0
41-50 mm
0
2 (5.9)
1 (11.1)
>50 mm
0
4 (11.8)
1 (11.1)
Number of metastases
<0.001
1
4 (36.4)
1 (2.9)
4 (44.4)
2
0
2 (5.9)
4 (44.4)
3
4 (36.4)
6 (17.6)
0
>3
3 (27.3)
25 (73.5)
1 (11.1)
LTP or IDR
0.68
Absent
7 (63.6)
18 (52.9)
4 (44.4)
Present
4 (36.4)
16 (47.1)
5 (55.6)
Extrahepatic progression
0.04
Absent
9 (81.8)
24 (70.5)
3 (33.3)
Present
2 (18.2)
10 (29.5)
6 (66.7)
MWA: microwave ablation, ECOG PS: Eastern Cooperative Oncology Group performance status, LTP: local tumor
progression, IDR: intrahepatic distant recurrence
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No incomplete ablation was observed in the first month
follow-up after MWA. The rate of LTP after treatment was
7.4% (n=4) and the rate of IDR was 46.3% (n=25). In
46.3% (n=25) of the patients, total response was achieved
(Figure 1).

The median OS was 49.2 months after MWA, 39.4
months after surgery, and 53.1 months after the combined
treatment. The median HPFS was 14.2 months (95% CI
10.0-18.3). There were no significant differences in HPFS
and OS between the three groups (p=0.56 and 0.90,
respectively) (Figures 2 and 3).

Figure 2. Hepatic progression-free survival of patients
with colorectal liver metastases after microwave
ablation (MWA), surgery, and combined treatment.

Figure 3. Overall survival of patients with hepatic
metastases from colorectal cancer following surgery,
microwave ablation (MWA), and combined treatment.

Figure 1. Local tumor progression in a 65-year-old
patient with colon cancer. (a) T2-weighed image shows
a hyperintense metastasis with a diameter of 3 cm in
segment V near the gallbladder bed and portal vein
branch, which was treated with microwave ablation
therapy. (b) Three metastases in the left lobe (black
asterisks), which were resected via lobectomy, are seen
on T2-weighed image. (c) At 1-year follow-up, a local
tumor progression (white asterisk) adjacent to a portal
vein branch (arrow) is encountered on postcontrast T1weighed image.
128

The univariate analysis revealed that patients with
ECOG performance status 2, RAS mutation, three or more
liver metastases, and those treated with percutaneous MWA
had significantly worse HPFS (p=0.041, 0.035, 0.026 and
0.001, respectively). On the multivariate analysis, the time
of liver metastasis occurrence (synchronous or
metachronous) and the number of CLMs (<3 or ≥ 3) were
independent prognostic factors for HPFS (HR 3.31, 95% CI
0.97-4.26, p=0.035; HR 1.56, 95% CI 0.99-2.46, p=0.031,
respectively). On the univariate analysis, the significant
factors associated with better OS were the absence of
extrahepatic progression (p=0.006) and the local treatment
response (p=0.005), while the extrahepatic progression
following the treatment remained an independent prognostic
factor on multivariate analysis (HR 5.74, 95% CI 1.35-10.4,
p=0.017). The logistic regression analysis revealed that
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patients younger than 60-years old, with smaller or fewer
metastases, and wild-type RAS showed significantly higher
rates of local treatment response (OR 0.22, 95% CI 0.15-

0.93, p=0.04; OR 1.12, 95% CI 0.54-2.12, p=0.029; OR
1.37, 95% CI 0.97-2.37, p=0.035; OR 0.23, 95% CI 0.100.85, p=0.028, respectively) (Table 2).

Table 2. Logistic regression analysis of the predictive factors for local treatment response
Factors
Age
(<60 vs. >60)
Local treatment procedure
(MWA vs. MWA-surgery vs. surgery)
Diameter of the largest metastasis (mm)
Number of metastases
(0 vs. 1. vs. 2. vs. 3. vs. >3)
RAS mutation
(wild type vs. mutant)

P

OR

95% CI

0.04

0.22

0.15-0.93

0.57

1.35

0.46-3.39

0.029
0.035

1.12
1.37

0.54-2.12
0.97-2.37

0.028

0.23

0.10-0.85

OR: Odds ratio, CI: confidence interval, MWA: microwave ablation

Discussion
Our study demonstrates the non-inferiority of MWA
compared with surgical resection and combined treatment.
Additionally, younger age (<60), smaller (≤ 2 cm) or fewer
(≤3) CLMs, and the presence of wild-type RAS mutation
were proven to be predictive factors for local tumor control.
Despite the fact that the surgical resection has been
considered the sole curative treatment for CLMs, only 10%
of the patients are eligible for surgery even with the
progress in systemic chemotherapy regimens and surgical
techniques, and five-year OS after surgery has been
reported as 25-46% [2,14,15]. Herein, thermal ablation
techniques including cryoablation, RFA, and MWA have
emerged as an alternative. Their main advantages include
the preservation of the liver volume, repeatability, realtime imaging, low morbidity and mortality rates, and low
costs. Moreover, they do not require hospitalization and
enable combined treatment with other modalities. Due to
their minimally invasive nature, these methods could
potentially be applied to a larger patient population [5,6].
In this aspect RFA is the most investigated thermal
ablation technique, but MWA offers several advantages
over RFA, as it is not affected by desiccation or charring,
provides larger and more homogenous ablation area more
rapidly, does not require grounding pads, and enables the
use of multiple antenna simultaneously [16,17].
The relatively higher LTP/IDR rate is the main drawback
limiting ablation as a first-line curative means [7,10,18]. The
LTP rates of MWA in heterogeneous study populations with
primary and secondary liver malignancies vary between 2.934% [11,19]. Our results revealing a relatively lower LTP
rate (7.4%) gives hope for the future.
Most of the studies in the existing literature focus on
both primary and metastatic hepatic tumors. Hence, it is
hard to make an exact comparison regarding the clinical
outcome [7-10,20]. Therefore, the results of our study
focusing only on CLMs and comparing different treatment

modalities, and analyzing distinct prognostic and
predictive factors for local treatment response provide a
significant contribution to the literature.
Although there are many studies in the existing
literature comparing different ablation methods and
defining the factors affecting the clinical outcome, none of
them set a cut-off value for the patients’ age regarding the
local treatment response [2,8,11,12,19-23]. Therefore, one
of the main strengths of our study is the correlation of the
outcomes with the patients’ age.
The results of a study evaluating the safety and the
efficiency of MWA in a heterogeneous population including
patients with hepatocellular carcinoma and CLMs revealed
that the tumor size did not affect the local treatment response
[9]. However, in our study, three or fewer lesions and lesions
smaller than two cm in the largest diameter resulted in higher
rates of local treatment response.
In a prospective randomized trial, namely the
COLLISION trial, investigating the non-inferiority of
thermal ablation techniques compared with surgical
resection, the patient population was divided into two
groups, i.e. the surgical and the thermal ablation group. The
latter included patients undergoing either RFA or MWA.
Their report revealed that surgery should not be regarded
as superior to ablation techniques. In lesions with a
diameter ≤3 cm, ablation techniques provided similar
results to surgery. Furthermore, they emphasized lower
mortality and morbidity rates, shorter hospitalization
duration and lower costs of ablation therapies. This study
does not completely reflect the results of the MWA group
due to the heterogeneity of the ablation group including
both RFA and MWA [6]. Our study with a wider range of
lesions regarding the largest diameter also revealed that
there was no significant difference between MWA and
surgery in local treatment response, OS, and HPFS.
There is only one prospective randomized trial focusing
solely on MWA as the thermal ablation method in the
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literature. The study population comprised 30 patients with
multiple CLMs and it was divided into MWA only and
hepatic resection only groups. The 1-, 2- and 3-year survival
rates and the mean survival times were reported as 71%,
57%, 14% and 27 months, respectively, for the MWA group
and 69%, 56%, 23% and 25 months for patients undergoing
hepatectomy. No significant difference was found between
the two groups (p=0.65). As a result of this study, MWA is
proved to be as effective as surgical resection in the
treatment of less than ten CLMs [21]. A study with 53
patients undergoing either hepatectomy (37 patients) or
MWA plus hepatectomy (16 patients) investigated the
treatment efficiency and compared the results including
survival and recurrence rates. The results revealed no
significant difference between the groups in OS, HPFS, and
disease-free survival (p=0.43, 0.54, and 0.86, respectively)
[2]. They emphasized the role of ablation methods in
expanding the indications of surgery in patients with
multiple CLMs. Our study involved an additional group
undergoing only MWA and so enabled a comparison of the
results from MWA, surgery, and combined treatment in a
wide range of lesions regarding the number and the largest
diameter of the metastasis, which adds a primary
contribution to the literature.
A multi-institutional study evaluating the survival rates
after MWA and combined treatment revealed no
significant differences in disease-free survival and OS
between the groups (p=0.525 and 0.132, respectively) [23].
Several cohort studies reported 3-, 4- and 5-year OS after
MWA between 35-79%, 35-58% and 17-18% [11,19,21].
These results are also compatible with our study, showing
no significant differences in HPFS and OS between the
MWA alone, surgery alone and combined treatment groups
(p=0.56 and 0.90, respectively).
We conducted a case-based approach in the treatment
of CLMs, in accordance with the guidelines of CIRSE and
the consensus report of COLLISION trial [6,12]. The
choice of the treatment modality was decided by a
multidisciplinary board according to the number, the size,
the location (proximity to the vasculo-biliary structures or
deep in the parenchyma) of the CLM. This approach might
be beneficial for customized treatment strategies. The
results of our study revealing no significant difference in
survival rates and local treatment response between the
groups might reflect the successful assignment of the
patients to different treatment options.
Patients with a poor ECOG performance status and
three or more liver metastases showed worse HPFS
(p=0.041 and 0.026, respectively) in our study. This can be
explained by the fact that these patients have a higher
tumor burden. The number of CLMs was also an
independent prognostic factor for HPFS (p=0.031). As
expected, achieving complete ablation and the absence of
extrahepatic progression were associated with better OS
130

(p=0.006 and 0.005, respectively). A report from the
literature suggests that a tumor size of three cm or more
was a predictive factor for HPFS in patients with hepatic
malignancies [8]. In a more recent study, the maximum
diameter of CLMs and patients’ response to pre-ablation
systemic chemotherapy were independent risk factors for
both OS and HPFS [22]. In our study, the diameter of the
largest metastasis was an independent predictive factor for
local treatment response (p=0.029).
According to a recent study, prehepatectomy
carcinoembryonic antigen concentration in serum served
as an independent prognostic factor for survival, which did
not differ between the resection and the combined
treatment group (p=0.02) [2]. Likewise, RAS mutation, a
genetic biomarker, was also found to be the main predictive
factor for the local treatment response (p=0.028) in our
study. These results are compatible with the studies in the
literature reporting lower HPFS rates of mutant RAS
compared to wild-type RAS [24,25].
A meta-analysis comparing ablation therapies with
surgical procedures for CLMs evaluated 75 studies and
concluded that ablative therapies offer significantly higher
survival rates and lower complication rates [11]. Major
complication rates of MWA varies between 2.6% and 16% in
the literature [11,20,26]. In our study, no major complication
occurred following MWA alone. A total of 9 patients (26.5%)
in the combined treatment group and 2 (22.2%) in the surgery
alone group experienced major complications such as abscess,
biloma and pleural effusion requiring drainage. In this regard,
MWA could be regarded as a safe technique.
The limitations of our study include retrospective design,
potential population bias, a relatively small sample size and a
limited follow-up interval. The main reason why there were
considerably fewer patients in the only-surgery group was the
widely accepted use of combined treatment with ablation
methods. Even though patients with more advanced disease
and metastases in proximity to vasculo-biliary structures were
referred to MWA, and more favorable patients underwent
surgical resection, MWA achieved similar outcomes, either
alone or as adjunct to surgery. Finally, one of the main
disadvantages of our study is the lack of ability to compare
systemic treatment response. Although the results of our study
reveal promising results regarding the role of MWA, studies
with larger sample sizes and longer follow-up duration are
required for further validation.

Conclusions
In conclusion, MWA as a minimally invasive and easily
repeatable curative method might achieve similar survival
rates compared to surgical resection and provide high local
tumor control in the treatment of patients with CLMs
whose life expectancy has been increased. In all these
aspects, we believe that MWA will be preferred over
surgical procedures in the near future.
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